Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 5/20 | 0.42 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.35 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.35 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.35 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.35 |
| ▸ | TK1 | P04183 | 2/20 | 0.35 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.35 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.34 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.34 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.34 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21786906 | 0.84 | TK1 (0.52) | TK1RNASE1 | |
| SCHEMBL24905837 | 0.83 | P2RY2 (0.56) | DUTP2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL23734157 | 0.83 | P2RY2 (0.56) | DUTP2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL21786869 | 0.81 | POLB (0.43) | SLC29A1P2RY2P2RY6P2RY4 | |
| SCHEMBL21787138 | 0.81 | POLB (0.43) | SLC29A1P2RY2P2RY6P2RY4 | |
| SCHEMBL26268704 | 0.81 | DUT (0.47) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL12015134 | 0.81 | DUT (0.47) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL12087561 | 0.81 | DUT (0.47) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL23102038 | 0.80 | DUT (0.46) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL23188292 | 0.80 | DUT (0.46) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200069717-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069717-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | POLRMT, NSUN2, RNGTT | DUT 21/4885SLC28A1 132/4885SLC28A2 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.